Natural products targeting tumour angiogenesis
- Publication type:
- Journal article
- Metadata:
-
- Autoren
- Xiaohua Lu
- Lara Johanna Friedrich
- Thomas Efferth
- Autoren-URL
- https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:001078696300001&DestLinkType=FullRecord&DestApp=WOS_CPL
- DOI
- 10.1111/bph.16232
- eISSN
- 1476-5381
- Externe Identifier
- Clarivate Analytics Document Solution ID: T5WR8
- PubMed Identifier: 37680009
- ISSN
- 0007-1188
- Zeitschrift
- BRITISH JOURNAL OF PHARMACOLOGY
- Schlüsselwörter
- natural products
- phytochemicals
- targeted chemotherapy
- tumour angiogenesis
- VEGFR-2 inhibitors
- Datum der Veröffentlichung
- 2023
- Status
- Published
- Titel
- Natural products targeting tumour angiogenesis
- Sub types
- Review
- Early Access
Data source: Web of Science (Lite)
- Other metadata sources:
-
- Abstract
- <jats:title>Abstract</jats:title><jats:p>Tumour angiogenesis is the formation of new blood vessels to support the growth of a tumour. This process is critical for tumour progression and metastasis, making it an attractive approach to cancer therapy. Natural products derived from plants, animals or microorganisms exert anti‐angiogenic properties and can be used to inhibit tumour growth and progression. In this review, we comprehensively report on the current status of natural products against tumour angiogenesis from four perspectives until March 2023: (1) the role of pro‐angiogenic factors and antiangiogenic factors in tumour angiogenesis; (2) the development of anti‐tumour angiogenesis therapy (monoclonal antibodies, VEGFR‐targeted small molecules and fusion proteins); (3) the summary of anti‐angiogenic natural agents, including polyphenols, polysaccharides, alkaloids, terpenoids, saponins and their mechanisms of action, and (4) the future perspectives of anti‐angiogenic natural products (bioavailability improvement, testing of dosage and side effects, combination use and discovery of unique natural‐based compounds). Our review aims to better understand the potential of natural products for drug development in inhibiting tumour angiogenesis and further aid the effective transition of these outcomes into clinical trials.</jats:p>
- Autoren
- Xiaohua Lu
- Lara Johanna Friedrich
- Thomas Efferth
- DOI
- 10.1111/bph.16232
- eISSN
- 1476-5381
- ISSN
- 0007-1188
- Zeitschrift
- British Journal of Pharmacology
- Sprache
- en
- Online publication date
- 2023
- Status
- Published online
- Herausgeber
- Wiley
- Herausgeber URL
- http://dx.doi.org/10.1111/bph.16232
- Datum der Datenerfassung
- 2023
- Titel
- Natural products targeting tumour angiogenesis
Data source: Crossref
- Abstract
- Tumour angiogenesis is the formation of new blood vessels to support the growth of a tumour. This process is critical for tumour progression and metastasis, making it an attractive approach to cancer therapy. Natural products derived from plants, animals or microorganisms exert anti-angiogenic properties and can be used to inhibit tumour growth and progression. In this review, we comprehensively report on the current status of natural products against tumour angiogenesis from four perspectives until March 2023: (1) the role of pro-angiogenic factors and antiangiogenic factors in tumour angiogenesis; (2) the development of anti-tumour angiogenesis therapy (monoclonal antibodies, VEGFR-targeted small molecules and fusion proteins); (3) the summary of anti-angiogenic natural agents, including polyphenols, polysaccharides, alkaloids, terpenoids, saponins and their mechanisms of action, and (4) the future perspectives of anti-angiogenic natural products (bioavailability improvement, testing of dosage and side effects, combination use and discovery of unique natural-based compounds). Our review aims to better understand the potential of natural products for drug development in inhibiting tumour angiogenesis and further aid the effective transition of these outcomes into clinical trials.
- Addresses
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University Mainz, Mainz, Germany.
- Autoren
- Xiaohua Lu
- Lara Johanna Friedrich
- Thomas Efferth
- DOI
- 10.1111/bph.16232
- eISSN
- 1476-5381
- Externe Identifier
- PubMed Identifier: 37680009
- Funding acknowledgements
- Theophrastus Stiftung, Mühltal, Germany:
- Open access
- false
- ISSN
- 0007-1188
- Zeitschrift
- British journal of pharmacology
- Sprache
- eng
- Medium
- Print-Electronic
- Online publication date
- 2023
- Datum der Veröffentlichung
- 2023
- Status
- Published
- Publisher licence
- CC BY
- Datum der Datenerfassung
- 2023
- Titel
- Natural products targeting tumour angiogenesis.
- Sub types
- Review
- Journal Article
Data source: Europe PubMed Central
- Abstract
- Tumour angiogenesis is the formation of new blood vessels to support the growth of a tumour. This process is critical for tumour progression and metastasis, making it an attractive approach to cancer therapy. Natural products derived from plants, animals or microorganisms exert anti-angiogenic properties and can be used to inhibit tumour growth and progression. In this review, we comprehensively report on the current status of natural products against tumour angiogenesis from four perspectives until March 2023: (1) the role of pro-angiogenic factors and antiangiogenic factors in tumour angiogenesis; (2) the development of anti-tumour angiogenesis therapy (monoclonal antibodies, VEGFR-targeted small molecules and fusion proteins); (3) the summary of anti-angiogenic natural agents, including polyphenols, polysaccharides, alkaloids, terpenoids, saponins and their mechanisms of action, and (4) the future perspectives of anti-angiogenic natural products (bioavailability improvement, testing of dosage and side effects, combination use and discovery of unique natural-based compounds). Our review aims to better understand the potential of natural products for drug development in inhibiting tumour angiogenesis and further aid the effective transition of these outcomes into clinical trials.
- Date of acceptance
- 2023
- Autoren
- Xiaohua Lu
- Lara Johanna Friedrich
- Thomas Efferth
- Autoren-URL
- https://www.ncbi.nlm.nih.gov/pubmed/37680009
- DOI
- 10.1111/bph.16232
- eISSN
- 1476-5381
- Funding acknowledgements
- Theophrastus Stiftung, Mühltal, Germany:
- Zeitschrift
- Br J Pharmacol
- Schlüsselwörter
- VEGFR-2 inhibitors
- natural products
- phytochemicals
- targeted chemotherapy
- tumour angiogenesis
- Sprache
- eng
- Country
- England
- Datum der Veröffentlichung
- 2023
- Status
- Published online
- Titel
- Natural products targeting tumour angiogenesis.
- Sub types
- Journal Article
- Review
Data source: PubMed
- Author's licence
- CC-BY
- Autoren
- Xiaohua Lu
- Lara Johanna Friedrich
- Thomas Efferth
- Hosting institution
- Universitätsbibliothek Mainz
- Sammlungen
- DFG-491381577-H
- Resource version
- Published version
- DOI
- 10.1111/bph.16232
- File(s) embargoed
- false
- Open access
- true
- ISSN
- 0007-1188
- Zeitschrift
- British journal of pharmacology
- Schlüsselwörter
- 570 Biowissenschaften
- 570 Life sciences
- Sprache
- eng
- Open access status
- Open Access
- Datum der Veröffentlichung
- 2023
- Public URL
- https://openscience.ub.uni-mainz.de/handle/20.500.12030/9956
- Herausgeber
- Wiley
- Datum der Datenerfassung
- 2024
- Datum, an dem der Datensatz öffentlich gemacht wurde
- 2024
- Zugang
- Public
- Titel
- Natural products targeting tumour angiogenesis
- Ausgabe der Zeitschrift
- Version of Record (VoR)
Files
natural_products_targeting_tu-20240117111304722.pdf
Data source: OPENSCIENCE.UB
- Beziehungen:
- Property of